Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2

Cell Death and Differentiation

Volumn 18, Issue 8, 2011, Pages 1376-1386

  Darding, M ^a   Feltham, R ^b   Tenev, T ^a   Bianchi, K ^a   Benetatos, C ^c   Silke, J ^b   Meier, P ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b LA TROBE UNIVERSITY   (Australia)

^c TetraLogic Pharmaceuticals   (United States)

Author keywords

cIAP1; cIAP2; Smac mimetic; TNF ; TRAF2; ubiquitin

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ARTICLE; CANCER CELL; CELL STRAIN HEK293; CONTROLLED STUDY; DIMERIZATION; GENE EXPRESSION; MOLECULAR DYNAMICS; ONCOGENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; RING FINGER MOTIF; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CASPASES; CELL DEATH; FIBROBLASTS; GENE EXPRESSION REGULATION; HEK293 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; MITOCHONDRIAL PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; RNA, SMALL INTERFERING; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA;

INTRACISTERNAL A-PARTICLES;

EID: 79960224920     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.10     Document Type: Article

References (41)

1. Chen DJ, Huerta S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 2009; 20: 646-658.
2. Vaux DL, Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003; 304: 499-504. (Pubitemid 36506522)
3. Cossu F, Mastrangelo E, Milani M, Sorrentino G, Lecis D, Delia D et al. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem Biophys Res Commun 2009; 378: 162-167.
4. Yang YL, Li XM. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10: 169-177.
5. Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, Zender L, Xue W et al. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-|[kappa]|B as well as cell survival and oncogenesis. Nat Cell Biol 2008; 10: 1309-1317.
6. Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A et al. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J 2009; 417: 149-160.
7. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem 2009; 284: 21777-21781.
8. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol 2008; 9: 1364-1370.
9. Bertrand M, Milutinovic S, Dickson K, Ho W, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700. (Pubitemid 351818251)
10. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
11. Vince J, Wong W, Khan N, Feltham R, Chau D, Ahmed A et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693. (Pubitemid 350103599)
12. Varfolomeev E, Blankenship J, Wayson S, Fedorova A, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB Activation, and TNFalphadependent apoptosis. Cell 2007; 131: 669-681. (Pubitemid 350087204)
13. Mahoney D, Cheung H, Mrad R, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNF{alpha}-mediated NF-{kappa}B activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
14. Gaither A, Porter D, Yao Y, Borawski J, Yang G, Donovan J et al. A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling. Cancer Res 2007; 67: 11493-11498.
15. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-288. (Pubitemid 38610351)
16. Bianchi K, Meier P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol Cell 2009; 36: 736-742.
17. Petersen S, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456. (Pubitemid 350064365)
18. Wong W, Gentle I, Nachbur U, Anderton H, Vaux D, Silke J. RIPK1 is not essential for TNFR1-induced activation of NF-kappaB. Cell Death Differ 2009; 17: 482-487.
19. Petersen SL, Peyton M, Minna JD, Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 2010; 107: 11936-11941.
20. Vince J, Pantaki D, Feltham R, Mace P, Cordier S, Schmuckle A et al. TRAF2 must bind to cIAPs for TNF to efficiently activate NF-{kappa}B and to prevent TNF-induced apoptosis. J Biol Chem 2009; 284: 35906-35915.
21. Samuel T, Welsh K, Lober T, Togo S, Zapata J, Reed J. Distinct BIR domains of cIAP1 mediate binding to and ubiquitination of tumor necrosis factor receptor-associated factor 2 and second mitochondrial activator of caspases. J Biol Chem 2006; 281: 1080-1090.
22. Varfolomeev E, Wayson SM, Dixit VM, Fairbrother WJ, Vucic D. The inhibitor of apoptosis protein fusion c-IAP2.MALT1 stimulates NF-kappaB activation independently of TRAF1 AND TRAF2. J Biol Chem 2006; 281: 29022-29029. (Pubitemid 44507046)
23. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008; 9: 1371-1378.
24. Grech AP, Amesbury M, Chan T, Gardam S, Basten A, Brink R. TRAF2 differentially regulates the canonical and noncanonical pathways of NF-kappaB activation in mature B cells. Immunity 2004; 21: 629-642. (Pubitemid 39487887)
25. Gardam S, Sierro F, Basten A, Mackay F, Brink R. TRAF2 and TRAF3 signal adapters act cooperatively to control the maturation and survival signals delivered to B cells by the BAFF receptor. Immunity 2008; 28: 391-401.
26. Feltham R, Moulin M, Vince JE, Mace PD, Wong WW, Anderton H et al. Tumor necrosis factor (TNF) signaling, but not TWEAK (TNF-like weak inducer of apoptosis)-triggered cIAP1 (cellular inhibitor of apoptosis protein 1) degradation, requires cIAP1 RING dimerization and E2 binding. J Biol Chem 2010; 285: 17525-17536.
27. Mace P, Linke K, Feltham R, Schumacher F, Smith C, Vaux D et al. Structures of the cIAP2 ring domain reveal conformational changes associated with E2 recruitment. J Biol Chem 2008; 283: 31633-31640.
28. Conze D, Albert L, Ferrick D, Goeddel D, Yeh W, Mak T et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol Cell Biol 2005; 25: 3348-3356. (Pubitemid 40464334)
29. Wang L, Du F, Wang X. TNF-α induces two distinct caspase-8 activation pathways. Cell 2008; 133: 693-703. (Pubitemid 351636305)
30. Isaacson PG, Du M-Q. Gastrointestinal lymphoma: where morphology meets molecular biology. J Pathol 2005; 205: 255-274. (Pubitemid 40227996)
31. Zhou H, Du M-Q, Dixit VM. Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 2005; 7: 425-431. (Pubitemid 40719126)
32. Hong SY, Yoon WH, Park JH, Kang SG, Ahn JH, Lee TH. Involvement of two NF-kappa B binding elements in tumor necrosis factor alpha-, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. J Biol Chem 2000; 275: 18022-18028. (Pubitemid 30414748)
33. Wang C-Y, Mayo M, Korneluk R, Goeddel D, Baldwin A. NF-B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998; 281: 1680.
34. Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 2007; 12: 1543-1568. (Pubitemid 47106887)
35. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004; 23: 8105-8117. (Pubitemid 39531851)
36. Hu Y, Cherton-Horvat G, Dragowska V, Baird S, Korneluk RG, Durkin JP et al. Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. Clin Cancer Res 2003; 9: 2826-2836. (Pubitemid 36842129)
37. Shaw TJ, Lacasse EC, Durkin JP, Vanderhyden BC. Downregulation of XIAP expression in ovarian cancer cells induces cell death in vitro and in vivo. Int J Cancer 2008; 122: 1430-1434. (Pubitemid 351287247)
38. Yin Q, Lamothe B, Darnay B, Wu H. Structural basis for lack of E2 interaction in the RING of TRAF2. Biochemistry 2009; 48: 10558-10567.
39. Zheng C, Kabaleeswaran V, Wang Y, Cheng G, Wu H. Crystal structures of the TRAF2: cIAP2 and the TRAF1: TRAF2: cIAP2 complexes: affinity, specificity, and regulation. Mol Cell 2010; 38: 101-113.
40. Mace PD, Smits C, Vaux DL, Silke J, Day CL. Asymmetric recruitment of cIAPs by TRAF2. J Mol Biol 2010; 400: 8-15.
41. Hosokawa Y, Suzuki H, Nakagawa M, Lee TH, Seto M. API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation. Biochem Biophys Res Commun 2005; 334: 51-60. (Pubitemid 40978506)